| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
in00004771382 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
200414s2020 enk ob 001 0 eng d |
| 005 |
20240206230855.8 |
| 035 |
|
|
|a (OCoLC)on1150785382
|
| 040 |
|
|
|a CAMBR
|b eng
|e rda
|e pn
|c CAMBR
|d OCLCO
|d UIU
|d OCLCF
|d HS0
|d EQF
|d BECOE
|d VT2
|d OCLCQ
|d EMU
|d OCLCO
|d UKAHL
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 019 |
|
|
|a 1165181354
|a 1165855154
|a 1165972751
|a 1228547764
|
| 020 |
|
|
|a 9781108864121
|q (electronic bk.)
|
| 020 |
|
|
|a 1108864120
|q (electronic bk.)
|
| 020 |
|
|
|a 1108799450
|
| 020 |
|
|
|a 9781108799454
|
| 020 |
|
|
|z 9781108799454
|q (paperback)
|
| 035 |
|
|
|a (OCoLC)1150785382
|z (OCoLC)1165181354
|z (OCoLC)1165855154
|z (OCoLC)1165972751
|z (OCoLC)1228547764
|
| 050 |
|
4 |
|a QR177
|b .C43 2020
|
| 082 |
0 |
4 |
|a 616.9041
|2 23
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Challenges to tackling antimicrobial resistance :
|b economic and policy responses /
|c edited by Michael Anderson, Michele Cecchini, Elias Mossialos.
|
| 264 |
|
1 |
|a Cambridge :
|b Cambridge University Press,
|c 2020.
|
| 300 |
|
|
|a 1 online resource (xxi, 250 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a European Observatory on Health Systems and Policies
|
| 520 |
|
|
|a Antimicrobial resistance (AMR) is a biological mechanism whereby a micro-organism evolves over time to develop the ability to become resistant to antimicrobial therapies such as antibiotics. The drivers of and potential solutions to AMR are complex, often spanning multiple sectors. The internationally recognised response to AMR advocates for a 'One Health' approach, which requires policies to be developed and implemented across human, animal, and environmental health. To date, misaligned economic incentives have slowed the development of novel antimicrobials and limited efforts to reduce antimicrobial usage. However, the research which underpins the variety of policy options to tackle AMR is rapidly evolving across multiple disciplines such as human medicine, veterinary medicine, agricultural sciences, epidemiology, economics, sociology and psychology. By bringing together in one place the latest evidence and analysing the different facets of the complex problem of tackling AMR, this book offers an accessible summary for policy-makers, academics and students on the big questions around AMR policy.
|
| 588 |
0 |
|
|a Vendor-supplied metadata.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a 1. Introduction / Michael Anderson, Anuja Chatterjee, Charles Clift, Elias Mossialos -- 2. The health and economic burden of antimicrobial resistance / Driss Ait Ouakrim, Alessandro Cassini, Michele Cecchini, Diamantis Plachouras -- 3. Tackling antimicrobial resistance in the community / Sarah Tonkin-Crine, Lucy Abel, Oliver van Hecke, Kay Wang, Chris Butler -- 4. Tackling antimicrobial resistance in the hospital sector / Rasmus Leistner, Inge Gyssens -- 5. Tackling antimicrobial resistance in the food and livestock sector / Jeroen Dewulf, Sussana Sternberg-Lewerin, Michael Ryan -- 6. Fostering R & D of novel antibiotics and other technologies to prevent and treat infection / Matthew Renwick, Elias Mossialos -- 7. Ensuring innovation for diagnostics for bacterial infection to combat antimicrobial resistance / Rosanna W. Peeling, Debrah Boeras, John Nkengasong -- 8. The role of vaccines in combating antimicrobial resistance / Mark Jit, Ben Cooper -- 8. The role of civil society in tackling antimicrobial resistance / Anthony So, Reshma Ramachandran.
|
| 650 |
|
0 |
|a Drug resistance in microorganisms
|x Economic aspects.
|
| 650 |
|
0 |
|a Drug resistance in microorganisms
|x Government policy.
|
| 650 |
|
0 |
|a Drug development
|x Economic aspects.
|
| 650 |
|
0 |
|a Drug development
|x Government policy.
|
| 650 |
|
6 |
|a Médicaments
|x Développement
|x Aspect économique.
|
| 650 |
|
6 |
|a Médicaments
|x Développement
|x Politique gouvernementale.
|
| 650 |
|
7 |
|a Drug development
|2 fast
|
| 650 |
|
7 |
|a Drug resistance
|2 fast
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Anderson, Michael
|c (Research officer),
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjFyTHTkRc9KHbBgK9rXMK
|
| 700 |
1 |
|
|a Cecchini, Michele,
|e editor.
|
| 700 |
1 |
|
|a Mossialos, Elias,
|e editor.
|
| 710 |
2 |
|
|a Cambridge University Press.
|
| 776 |
0 |
|
|z 1108799450
|
| 830 |
|
0 |
|a European Observatory on Health Systems and Policies series.
|
| 856 |
4 |
0 |
|u https://doi.org/10.1017/9781108864121
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Cambridge Open Access ebooks
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|s 707edaf1-060c-4fdd-ab18-1a9cd113485e
|i 9eeeb693-3a64-47e8-bbc2-4204df9ba9fe
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e QR177 .C43 2020
|h Library of Congress classification
|
| 998 |
f |
f |
|a QR177 .C43 2020
|t 0
|l Available Online
|